Shenzhen TargetRx, Inc. has successfully secured an impressive $50 million in funding, a significant boost for the clinical stage pharmaceutical R&D company dedicated to revolutionizing cancer treatment. TargetRx specializes in developing next-generation targeted therapies, particularly for cancer patients who have become resistant or refractory to existing therapies. By leveraging cutting-edge and efficient small molecule drug discovery platforms, the company has established itself as a leader in innovative research and development, marked by an extensive portfolio of over 170 patents across major global markets, including China, the US, Europe, and Japan. This recent funding will primarily enhance TargetRx's capabilities in drug design, screening, and optimization, enabling the continued advancement of several promising compounds currently undergoing multi-national clinical trials. The capital will also be directed toward accelerating the development timeline of these therapies, aiming to address the unmet medical needs of cancer patients worldwide. With a commitment to excellence and groundbreaking advancements in oncology, TargetRx is poised to make a substantial impact on how cancer is treated, paving the way for more effective and personalized solutions for patients in desperate need of new options. For further inquiries about partnerships or the technology, please reach out to BD contact Shujun Mai at shujun.mai@tjrbiosciences.com.
Shenzhen TargetRx, Inc. Secures $50 Million in Series C Funding for Groundbreaking Cancer Therapies
Recently funded 路 $50.0M Series cPharmaceutical
Get the full Shenzhen TargetRx, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
